Esperion product candidates represent a multi-target approach to positive lipid management to treat disease.

The Esperion dyslipidemia program is aimed at identifying small molecules, i.e., oral medications, to treat abnormal lipid metabolism. ETC-1002 is the flagship product of this program. ETC-1002 is designed to treat dyslipidemia by favorably altering lipid metabolism in two ways: first, by inhibiting the fatty acid and cholesterol synthesis process, and second, by enhancing oxidation of fatty acids. Fatty acids are the building blocks of lipids. Inhibiting the synthesis process means to hinder the production of select lipids. Enhancing the oxidation process refers to improving the breakdown of lipids for energy production and easier elimination from the blood. We believe ETC-1002 can lead to favorable lipid changes and the easing of metabolic ailments in patients with dyslipidemia, diabetes, and obesity.

Esperion Development Pipeline

ETC 1002

ETC-1002 and its related intellectual property were developed by the original Esperion and were divested by Pfizer to the new Esperion in May 2008.

In addition to ETC-1002, Esperion is pursuing products designed to address a broad spectrum of treatment opportunities for both acute and chronic cardiovascular and metabolic conditions. We will continue to build our drug portfolio, acquiring new compounds and platform technologies in the lipid management field. And we will leverage our drug development experience and expertise to translate scientific research into novel therapies that can improve health and make lives better . Esperion is again paving a new path in biotech therapies for cardiovascular and metabolic disease.